厄洛替尼治疗晚期非小细胞肺癌近期疗效和安全性研究

目的 评价厄洛替尼治疗晚期非小细胞肺癌(NSCLC)的近期疗效.方法 21例确证的化疗失败的Ⅲb/Ⅳ期NSCLC患者入组,给予厄洛替尼150mg/d口服,直至疾病进展,观察近期疗效和不良反应.结果 21例患者中完全缓解0例,部分缓解7例,客观缓解率为33.3％；稳定6例,疾病控制率为61.9％；女性疾病控制率优于男性(P＜0.05),而吸烟、肿瘤类型、皮疹及腹泻均与客观缓解率和疾病控制率无关(P＞0.05)；主要毒副反应为1/2度皮疹和腹泻,发生率分别为80％和42.9％.结论 厄洛替尼能有效治疗晚期NSCLC,女性疗效更佳,且不良反应少.

Study on the short -term efficacy and safety of erlotinib in treatment of advanced non-small cell lung cancer

Objective To evaluate the short-term efficacy and safety of erlotinib on advanced non-small lung cell cancer(NSCLC).Methods Twenty-one patients with advanced NSCLC(Ⅲb/Ⅳstage),who failed to prior chemotherapy,were enrolled in the study.Erlotinib(150 mg) was orally administered daily.Restults There were zero patients who got complete remission,seven patients who got partial remission and six patients whose condition was stable in total patients.Therefore,the objective remission rate is 33.3% and the disease control rate is 61.9%.The disease control rate of the female is prior to the male in the treatment efficacy of erlotinib(P<0.05).However,other correlation factors including smoking,tumor type,skin rash and diarrhea did not affect the objective remission rate and the disease control rate of erlotinib,respectively(all P>0.05).The major adverse reactions of erlotinib were shin rash with the incidence of 80% and diarrhea with the incidence of 42.9%,which were mostly in Ⅰ/Ⅱ degree.Conclusion Erlotinib is effective in treatment of advanced NSCLC with minor adverse reactions and its treatment efficacy in the female is prior to that in the male.